FDA Determines Regulatory Review Period for KEVZARA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for KEVZARA, a human biological product, following a request from the U.S. Patent and Trademark Office (USPTO) for patent extension.